Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

How to apply for vascepa's patient assistance?
When is tenofovir alafenamide patent expiring?
Does lipitor's effectiveness decrease with high fat meals?
Dabrafenib mesylate when the patent is expiring in india?
Are there specific stretches to avoid while on lipitor?

Is apixaban accord the same as apixaban?

See the DrugPatentWatch profile for apixaban

Short answer:
Yes – Apixaban Accord is essentially the same medication as generic apixaban. “Accord” is a brand name (often used in certain countries, e.g., in the United States it’s marketed as Eliquis; in other regions it may appear under other brand names). The active ingredient, the chemistry, and the therapeutic effect are identical.

What is Apixaban?

Category Details
Generic name Apixaban
Common brand names Eliquis (U.S.), Accord (in some markets), and others depending on region
Drug class Direct oral anticoagulant (DOAC); specifically, a factor Xa inhibitor
Uses • Prevention of stroke in non‑valvular atrial fibrillation (AF)
• Treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE)
• Prevention of recurrent venous thromboembolism (VTE)
Typical dosing • AF: 5 mg PO twice daily
• VTE treatment: 10 mg PO twice daily for 7–10 days, then 5 mg twice daily
• VTE prevention after orthopedic surgery: 2.5 mg PO twice daily
Administration Oral capsule, taken with or without food

Why Different Brand Names Matter

  • Brand name vs. generic – The same active drug can be sold under various brand names. The only differences are usually the manufacturer’s packaging, labeling, and sometimes a slight difference in excipients (inactive ingredients). These excipients rarely affect the drug’s safety or efficacy for most patients, but they can matter for people with allergies to specific fillers or for cost considerations.
  • Generic approval – In the U.S. and many other countries, the FDA/EU‑EMA and other regulators approve generic versions once they demonstrate “bioequivalence” to the original branded product. That means the drug reaches the bloodstream at essentially the same concentration and rate.

Key Points to Keep in Mind

Topic What to Know
Safety Common side effects: bleeding (gastrointestinal, intracranial), bruising, nausea. Rare: hypersensitivity reactions, thrombocytopenia.
Drug Interactions Strong CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin) can alter apixaban levels. Avoid concurrent use with other anticoagulants or antiplatelet agents unless supervised by a clinician.
Contraindications Active major bleeding, severe uncontrolled hypertension, significant liver disease (Child‑Pugh C), or known hypersensitivity to apixaban.
Monitoring Routine coagulation tests (PT/INR, aPTT) are not required. Check renal function every 6 months (or more often if impaired).
Pregnancy & Breastfeeding Limited data; generally not recommended unless benefits outweigh risks.

How to Tell the Difference on Your Pharmacy Bag

Label What to Look For
“Accord” Brand name; check the FDA/EMA approval number if you’re in the U.S.
“Eliquis” U.S. brand name; same active ingredient.
Generic Usually just “Apixaban” followed by the dosage strength (e.g., 5 mg).

If you’re ever unsure, the pharmacist or your prescribing clinician can confirm that the medication you have is indeed apixaban, regardless of the brand name.

Bottom Line

  • Apixaban Accord = Apixaban (generic) + brand label.
  • The drug’s pharmacology, approved uses, and safety profile are the same across brand and generic forms.
  • Always follow your prescriber’s instructions and discuss any concerns—especially if you’re taking other medications that may interact with apixaban.

Feel free to reach out if you have more questions about dosing, side effects, or how apixaban interacts with other drugs you might be taking!



Other Questions About Apixaban :

when does patent protection end in the eu, apixaban When does patent protection end in the eu apixaban? Apixaban brand name? Apixaban price in usa? Apixaban nombre comercial y generico? Apixaban generic name? Can i take apixaban and lipitor at the same time?

AI-Drug Label Prescribing Information Alignment Report

55
55%
Grade C

Partial

Mostly Aligned

Patient Risk: Moderate

Summary

Partially aligned: the only label-anchored, high-specificity claims about thrombotic risk after premature discontinuation and neuraxial/spinal-epidural hematoma are supported by the provided label excerpts. However, most other claims were not assessed against the provided label excerpts because the excerpt set does not contain corresponding sections (e.g., indications, contraindications, dosing specifics for brand switching, excipients, or equivalence/risks of substitution).

Category Scores

Indication
40
Partial
Dosage
45
Partial
Warnings
90
Excellent
DrugInteractions
30
Partial
Administration
50
Partial

Accurate Statements

Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events.
Section 5.1: “Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events.”
When neuraxial anesthesia or spinal/epidural puncture is employed in patients treated with antithrombotic agents, there is a risk of epidural or spinal hematoma which can result in long-term or permanent paralysis.
Section 5.3: “...patients treated with antithrombotic agents... are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis.”

Unsupported Statements

“Apixaban Accord” is apixaban manufactured under the Accord branding (Accord Healthcare).
The provided FDA label excerpts do not include manufacturing/brand-origin statements about “Apixaban Accord.”
“Apixaban Accord” contains the same active ingredient as apixaban, namely apixaban.
No provided label excerpt addresses this specific brand product’s formulation/active ingredient identity.
Apixaban is used to prevent blood clots.
The provided label excerpt set does not include an explicit, consolidated indication statement sufficient to verify this wording.
Apixaban is used to treat blood clots.
The provided label excerpt set does not include an explicit, consolidated indication statement sufficient to verify this wording.
For the same dosage strength and formulation, “Apixaban Accord” and apixaban are used with the same active ingredient.
The provided label excerpts do not discuss equivalence between “Apixaban Accord” and other apixaban products by brand.
Products with the same active ingredient can vary in brand name and paperwork.
The provided label excerpts do not address brand name/paperwork variation.
Products with the same active ingredient can vary in tablet strength (e.g., 2.5 mg vs 5 mg).
Although strengths are mentioned as examples in the prompt, the provided label excerpt set does not explicitly validate this statement within the auditing scope.
Products with the same active ingredient can vary in inactive ingredients (excipients).
No provided label excerpt discusses excipients across brands.
Inactive ingredients generally matter only for people with specific allergies or sensitivities.
No provided label excerpt states this generalization.
Switching between brands of apixaban (same strength, same route, same active ingredient) is considered equivalent in effect for most patients.
The provided label excerpts do not state that switching brands is equivalent for most patients.
Switching to a different strength than intended is a practical risk when switching between apixaban brands.
The provided label excerpts do not identify this as a labeled practical risk for brand switching.
Confusion over which formulation you actually take is a practical risk when switching between apixaban brands.
The provided label excerpts do not discuss confusion risk related to switching between apixaban brands.
Prescriber/pharmacy errors during substitution are a practical risk when switching between apixaban brands.
The provided label excerpts do not mention substitution-related prescriber/pharmacy error risks.

Contradictions

Important Omissions

Specific labeled indication(s), dosing regimens, and brand-switching/conversion guidance (including any cautions about switching between different apixaban products) are not provided in the excerpt set, but were implicitly relied upon by the response’s indication/equivalence claims.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
Most non-warning statements about brand switching/equivalence and brand-specific product identity are unsupported by the provided excerpts, creating a risk that a reader could infer interchangeability or safety/efficacy equivalence not verified by the supplied label text.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Mostly Aligned

Primary Issue
Large portions of the response make brand/product equivalence and substitution risk claims that are not supported by the provided FDA label excerpts.

Suggested Improvement
Limit claims to statements explicitly supported by the supplied label excerpts (e.g., Section 5.1 and 5.3 warnings). Remove or qualify brand-switching equivalence and excipient/substitution practical-risk assertions unless supported by provided label text.

Drug Brand Mention Assessment

Branding Score
49
Visibility
49
Mentioned
Ranking
#1
Sentiment
68
Recommendation Status
mentioned only
Brand Perception
Best Known For

apixaban made/manufactured under the Accord branding (Accord Healthcare)

Core Claims
  • “Apixaban Accord” is apixaban made/manufactured under the Accord branding
  • It’s the same active ingredient—apixaban
  • The effect assumes the same dosage strength and formulation
  • Differences are usually the brand/manufacturer, not the active medicine
  • Switching between brands (same strength/route/active ingredient) is considered equivalent in effect
Differentiators
  • Accord branding/manufacturer: “Apixaban Accord” vs “apixaban”
  • Can vary in tablet strength (e.g., 2.5 mg vs 5 mg)
  • Can vary in inactive ingredients (excipients)
Pricing Perception: Not Mentioned